Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

594 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours.
Vidal L, Victoria I, Gaba L, Martín MG, Brunet M, Colom H, Cortal M, Gómez-Ferrería M, Yeste-Velasco M, Perez A, Rodon J, Sohal DPS, Lizcano JM, Domènech C, Alfón J, Gascón P. Vidal L, et al. Among authors: brunet m. Eur J Cancer. 2021 Mar;146:87-94. doi: 10.1016/j.ejca.2020.12.019. Epub 2021 Feb 12. Eur J Cancer. 2021. PMID: 33588149 Clinical Trial.
Early prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients.
Quintairos L, Colom H, Millán O, Fortuna V, Espinosa C, Guirado L, Budde K, Sommerer C, Lizana A, López-Púa Y, Brunet M. Quintairos L, et al. Among authors: brunet m. PLoS One. 2021 Jan 22;16(1):e0245880. doi: 10.1371/journal.pone.0245880. eCollection 2021. PLoS One. 2021. PMID: 33481955 Free PMC article.
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.
Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Brunet M, et al. Ther Drug Monit. 2019 Jun;41(3):261-307. doi: 10.1097/FTD.0000000000000640. Ther Drug Monit. 2019. PMID: 31045868 Review.
Polyethylene Glycol Drug-Eluting Embolic Microspheres Loaded with Doxorubicin for the Treatment of Hepatocellular Carcinoma: Feasibility, Safety, and Pharmacokinetic Study.
Malagari K, Denys A, Burrel M, Reig M, Brunet M, Duran R, Kiakidis T, Moschouris H, Sanduzzi-Zamparelli M, Bruix J. Malagari K, et al. Among authors: brunet m. J Vasc Interv Radiol. 2022 Jul;33(7):752-761. doi: 10.1016/j.jvir.2021.11.019. Epub 2022 Mar 26. J Vasc Interv Radiol. 2022. PMID: 35351630
Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
Martínez-Rebollar M, Muñoz A, Pérez I, Hidalgo S, Brunet M, Laguno M, González A, Calvo M, Loncà M, Blanco JL, Martínez E, Gatell JM, Mallolas J. Martínez-Rebollar M, et al. Among authors: brunet m. Ther Drug Monit. 2013 Aug;35(4):552-6. doi: 10.1097/FTD.0b013e31828d50ef. Ther Drug Monit. 2013. PMID: 23851911
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials.
Díaz-González Á, Sapena V, Boix L, Brunet M, Torres F, LLarch N, Samper E, Millán O, Corominas J, Iserte G, Sanduzzi-Zamparelli M, da Fonseca LG, Darnell A, Belmonte E, Forner A, Ayuso C, Bruix J, Reig M. Díaz-González Á, et al. Among authors: brunet m. Liver Int. 2020 Oct;40(10):2476-2488. doi: 10.1111/liv.14587. Epub 2020 Jul 25. Liver Int. 2020. PMID: 33021346
594 results